Perceived benefits and cost savings of liquid formulation of intravenous infliximab: perspectives of seven European countries
{{output}}
Background: Following the approval of intravenous (IV) infliximab (IFX) in the 1990s, Celltrion developed the first monoclonal antibody biosimilar for IV IFX (Remsima®: Celltrion, South Korea), followed by the first and only sub... ...
